Blood tests, billion-dollar bets, and flat futures

🌅 Today's Morning Call

S&P Futures 7,679.25 ▼ -3.25 (-0.04%)	Nasdaq Futures 29,244.00 ▼ -27.00 (-0.09%)	Dow Futures 53,292.00 ▼ -35.00 (-0.07%)
10Y Treasury 4.74% ▲ +0.04%	US Dollar 98.96 ▲ +0.12 (+0.13%)	Bitcoin $78,183 ▲ +$457 (+0.59%)

Good morning! Monday, August 24 is here, and futures are doing their best impression of a shrug. The S&P 500, Nasdaq, and Dow are all pointing slightly lower pre-market, but the real action this morning is in the headlines, not the indices. From a landmark FDA clearance for an Alzheimer's blood test to a $2 billion UPS spending commitment, there is plenty to chew on before the opening bell. Here is what is moving this morning.

👀 What to Watch Today

With futures showing only modest losses, the session setup looks relatively calm on the macro side. Treasury yields are creeping higher across the board, with the 10-year sitting at 4.74% and the 30-year pushing 5.28%. That upward drift in yields is worth watching as it adds quiet pressure to rate-sensitive sectors like utilities and real estate.

The Dollar Index at 98.96 is nudging higher, which could weigh on multinational earnings stories. Bitcoin is showing a bit of life at $78,183, up just under 0.6%, but crypto is more of a sideshow today given the pharma and logistics headlines stealing the spotlight.

There are no major S&P 500 earnings reports scheduled for Monday, so the news-driven stories from the weekend and overnight will likely set the tone. Keep an eye on healthcare and logistics names specifically, as those are the sectors with the most active catalysts heading into today's open.

Only one company survived this screen [ad]

🌏 Overnight Recap

The big headline crossing over the weekend involves Eli Lilly (LLY) and Roche (RHHBY). The FDA cleared their jointly developed blood test designed to detect early signs of Alzheimer's disease in patients 55 and older showing cognitive decline. This is a meaningful commercial milestone for both companies, giving physicians a far less invasive diagnostic tool compared to PET scans or spinal fluid analysis.

On the tech and services front, India's Tata Consultancy Services announced it will acquire Porsche's IT division MHP for approximately $373 million, or 320 million euros. The deal expands TCS's footprint in European automotive IT services, though the direct market impact for U.S. investors centers on Porsche's ADR (POAHY) more than anything else.

GSK (GSK) also had a strong overnight news cycle. The company received its first global approval in Japan for its experimental chronic hepatitis B drug and scored a priority review designation from U.S. regulators for a cancer therapy. Two regulatory wins in one morning is the kind of news that tends to push a pharma name higher at the open, so watch GSK closely.

3 AI stocks to buy in August 2026 [ad]

📊 Pre-Market Movers

Eli Lilly (LLY) is the headline pre-market mover this morning following the FDA clearance of its Alzheimer's blood test developed with Roche (RHHBY, RHHBF). The test targets individuals 55 and older with cognitive decline, opening a significant new commercial avenue for LLY in an already busy pipeline year. Investors will be watching for early-session price action and whether analysts update price targets on the back of this news.

GSK (GSK) is another name worth pulling up on your screen before the bell. Japan's approval of its hepatitis B drug marks the first global regulatory win for that treatment, and a U.S. priority review for a cancer therapy adds a second catalyst in a single overnight window. Two pieces of positive regulatory news in one morning is unusual and the market tends to reward that.

UPS is also in the spotlight after confirming to CNBC a $2 billion-plus investment commitment spanning its international, healthcare, and supply chain divisions. The investments began in 2024 and continue through the coming years. That kind of capital deployment signal often reads as management confidence in forward demand, and it could give UPS shares a lift heading into the open.

AI insiders stockpile guns, gold & gas masks [ad]

🔍 Today's Watchlist

1. LLY: FDA-cleared Alzheimer's blood test is a potential revenue accelerant. Watch for analyst commentary on commercialization timelines throughout the session.
2. GSK: Dual regulatory wins overnight in hepatitis B and oncology. This stock could see notable pre-market and early-session buying interest.
3. UPS: A $2 billion investment commitment in international, healthcare, and supply chain is a bullish signal on long-term strategy. Watch how the market prices that conviction today.
4. Treasury yields: The 10-year at 4.74% and 30-year at 5.28% are both ticking higher. Any further move up could dampen enthusiasm in growth and rate-sensitive names.
5. Oil ETFs (BNO, DBO, GUSH): IEA chief Birol confirmed no discussions are underway for a second strategic reserve release. That keeps supply dynamics in focus for energy traders today.

🎯 The Morning Playbook

Today's playbook is essentially a tale of sector-specific catalysts against a muted macro backdrop. Futures are nearly flat, yields are slightly elevated, and there are no blockbuster earnings reports on the calendar. That means individual stock stories are going to do the heavy lifting in determining where money flows today.

Healthcare is the clear sector to watch. Between LLY's Alzheimer's test clearance and GSK's double regulatory win, pharma names are carrying real momentum into Monday's session. If you have positions in either, today is a day to monitor closely for analyst reactions and potential price target revisions that could extend early gains.

For everyone else, the broader message is simple: a quiet macro day is not the same as a boring day. Sometimes the most interesting moves come when the index-level noise is low and individual stories get room to breathe. Keep your watchlist tight, stay focused on the names with actual news behind them, and let the tape tell you what it wants to do.

The IRA Mistake That Could Cost Americans 55+ Thousands in 2026 [ad]